A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis

Multiple sclerosis

(2018) Alan J Thompson et al.   LANCET

Enhanced endocannabinoid tone as a potential target of pharmacotherapy

(2018) Marek Toczek et al.   LIFE SCIENCES

Resolvin D1 Halts Remote Neuroinflammation and Improves Functional Recovery after Focal Brain Damage Via ALX/FPR2 Receptor-Regulated MicroRNAs

(2018) Elisa Bisicchia et al.   MOLECULAR NEUROBIOLOGY

The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases

(2018) Valerio Chiurchiù et al.   PROGRESS IN NEUROBIOLOGY

Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect

(2018) Stefania Petrosino et al.   Frontiers in Pharmacology

The Flavone Luteolin Improves Central Nervous System Disorders by Different Mechanisms: A Review

(2018) Zeinab Ashaari et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

New approaches and challenges to targeting the endocannabinoid system

(2018) Vincenzo Di Marzo   NATURE REVIEWS DRUG DISCOVERY

Targeting NLRP3 Inflammasome in the Treatment of CNS Diseases

(2018) Bo-Zong Shao et al.   Frontiers in Molecular Neuroscience

Production of PEA composite microparticles with polyvinylpyrrolidone and luteolin using Supercritical Assisted Atomization

(2018) Renata Adami et al.   JOURNAL OF SUPERCRITICAL FLUIDS

Novel ureidopropanamide based N -formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation

(2017) Madia Letizia Stama et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The contribution of the acute phase response to the pathogenesis of relapse in chronic-relapsing experimental autoimmune encephalitis models of multiple sclerosis

(2017) Silvy Mardiguian et al.   Journal of Neuroinflammation

Co-Ultramicronized Palmitoylethanolamide/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells

(2017) Stephen D. Skaper et al.   MOLECULAR NEUROBIOLOGY

Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia

(2017) Rosalba Siracusa et al.   Frontiers in Neurology

Expression and Differential Responsiveness of Central Nervous System Glial Cell Populations to the Acute Phase Protein Serum Amyloid A

(2017) Massimo Barbierato et al.   Scientific Reports

The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

(2016) Stefania Petrosino et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells

(2016) Ewa Kozela et al.   Journal of Neuroinflammation

Neuroprotective Effects of Co-UltraPEALut on Secondary Inflammatory Process and Autophagy Involved in Traumatic Brain Injury

(2016) Marika Cordaro et al.   JOURNAL OF NEUROTRAUMA

Microglia activation states and cannabinoid system: Therapeutic implications

(2016) M. Mecha et al.   PHARMACOLOGY & THERAPEUTICS

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

(2016) Alessia Ligresti et al.   PHYSIOLOGICAL REVIEWS

Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury

(2016) Rosalia Crupi et al.   Frontiers in Pharmacology

Luteolin as an anti-inflammatory and neuroprotective agent: A brief review

(2015) Seyed Fazel Nabavi et al.   BRAIN RESEARCH BULLETIN

Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice

(2015) A. Rahimi et al.   NEUROSCIENCE

Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells

(2015) Massimo Barbierato et al.   Scientific Reports

Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man

(2015) Carlo Caltagirone et al.   Translational Stroke Research

Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation

(2014) Irene Paterniti et al.   CNS & Neurological Disorders-Drug Targets

To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis

(2014) Lucas Schirmer et al.   Multiple Sclerosis Journal

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

(2014) P. Browne et al.   NEUROLOGY

Palmitoylethanolamide in CNS health and disease

(2014) Giuseppina Mattace Raso et al.   PHARMACOLOGICAL RESEARCH

Effects of Palmitoylethanolamide and Luteolin in an Animal Model of Anxiety/Depression

(2013) Rosalia Crupi et al.   CNS & Neurological Disorders-Drug Targets

Endocannabinoids: A unique opportunity to develop multitarget analgesics

(2013) Sabatino Maione et al.   PAIN

Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain

(2013) Stephen D. Skaper et al.   INFLAMMOPHARMACOLOGY

Development of Experimental Autoimmune Encephalomyelitis Critically Depends on CD137 Ligand Signaling

(2012) J. M. Martinez Gomez et al.   JOURNAL OF NEUROSCIENCE

Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain

(2010) Harald S. Hansen   EXPERIMENTAL NEUROLOGY

Cutting Edge: NF- B Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression

(2009) F. G. Bauernfeind et al.   JOURNAL OF IMMUNOLOGY